




genetic technologies



ASX ANNOUNCEMENT

September 12th, 2005

GTG launches ACTN3 SportsGene Test™ in Japan

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce the official launch of its ACTN3 SportsGene Test™ in Japan.

At a ceremony held in Tokyo, GTG together with its Japanese distribution partner, Sportsstyle, launched the ACTN3 SportsGene Test™ to an audience of over 100 sports specialists, including the President of the Japan Federation of Health and Sports.

The launch of the ACTN3 SportsGene Test™ was widely reported in the Japanese press and represents the start of a major program with Sportsstyle that will see the ACTN3 SportsGene Test™ sold across its extensive Japanese distribution network.

GTG director, Professor Deon Venter, himself a former British Ironman Triathlon champion, attended the launch. Professor Venter commented "Japan represents a significant market for the ACTN3 SportsGene Test™, with highly influential sporting and government bodies keen to explore the relationship between genetics and sporting performance. Japan is an extremely technologically-sophisticated country and is now taking a leadership position in the science of optimising a person's sports potential according to their inherited genetic capabilities."

In conjunction with Sportsstyle, GTG held meetings with influential sporting bodies looking to use the ACTN3 SportsGene Test™ as part of their training and assessment program.

All commercial ACTN3 SportsGene Tests from Japan will be analysed at GTG's headquarter laboratory in Melbourne. The first tests are expected to arrive in the next two weeks.

FOR FURTHER INFORMATION PLEASE CONTACT

Mr. Geoff Newing
Group General Manager – Business Development

Genetic Technologies Limited
Phone: +61 3 9415 1135